Subcutaneous immunotherapy with house dust mite extract in Indonesian children with allergic rhinitis and asthma: A double-blind randomized controlled trial.
What's New
House dust mite subcutaneous immunotherapy was associated with reduced symptom scores and key immunological markers in Indonesian children with allergic rhinitis and asthma.
Detailed Summary
A double-blind RCT of 41 children with allergic rhinitis (n=20) or allergic rhinitis plus asthma (n=21) evaluated 14 weeks of weekly house dust mite SCIT. Treatment was associated with significant reductions in total IgE, TGF-β1, Combined Symptom Medication Score, and Visual Analogue Scale scores (p<0.05), though no significant differences in treatment effect were observed between the two groups.
Study Population
Indonesian children with house dust mite-related allergic rhinitis or allergic rhinitis plus asthma (n=41)
This research is for informational purposes only — discuss with your doctor before making any changes to your care.
Rivvet may earn a referral fee if you book through this link.